Zeria Pharmaceutical

Basic Information

Stock Code: 4559
Industry: Pharmaceuticals
Category Detail: Biotechnology & Pharmaceuticals
Prefecture: Tokyo
Establishment Year: December 1955
Listing Year: December 1998
Official Website: https://www.zeria.co.jp/
TSE Information: TSE Information
Yahoo! Finance: Yahoo! Finance
Other Companies: Neo Japan, Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Nippon Shinyaku, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Santen Pharmaceutical, Fuji Pharma, Daiichi Sankyo, Otsuka Holdings

Overview

Zeria Pharmaceutical is a pharmaceutical company founded in 1955, primarily manufacturing and selling gastrointestinal prescription drugs and chondroitin formulations both domestically and internationally.

Current Situation

Zeria Pharmaceutical achieved consolidated sales of ¥60.4 billion and operating profit of ¥4.1 billion in the fiscal year ending March 2020, establishing itself as a competitive pharmaceutical company centered on gastrointestinal treatments. The company has strengths in over-the-counter chondroitin formulations, with its flagship brand Chondroitin ZS Tablets recognized as an industry leader. The acquisition of Swiss Tylotix has expanded its overseas operations, involving drug development, manufacturing, and sales in Europe and various Asian countries. In product development, it maintains a diverse portfolio including prescription drugs for ulcerative colitis and advances research and development. As part of its social responsibility, it focuses on quality management and sustainability initiatives, while learning from the 2017 black training scandal to improve its human resource development system. To adapt to changing market environments, it pursues new product development and strengthening its global network, planning subsidiary absorptions and mergers from 2025 onward to bolster its corporate structure. It promotes business diversification and customer base expansion, aiming for sustainable growth.

Trivia

Interesting Facts

Zeria's namesake chondroitin formulations have long been famous.
Gained attention for the 2017 black training issue and subsequently overhauled its training system.
Acquired Swiss Tylotix to increase presence in the European market.
Specializes in gastrointestinal pharmaceuticals while diversifying into popular tonics.
Maintains strong brand power in tonic drinks and gastrointestinal medicines.
Features balanced business across prescription and OTC segments.
Hepalyse W soft drink type is a popular convenience store exclusive.
Some skincare products co-developed with Shiseido.
Actively expanding overseas with concentrated R&D in Europe.
Actively adding new lines such as constipation and skin treatment drugs.
Efforts to improve customer satisfaction through smaller tablets and additive changes.
Uses celebrities aligned with brand image for advertising to boost recognition.
Prescription pharmaceuticals include co-sold products with companies like Shionogi.
Progressing toward integrated management via subsidiary absorptions.
Built high trust as a pharmaceutical manufacturer maintaining safety and quality.

Hidden Connections

Strong foothold in European drug market via Swiss Tylotix acquisition
Tonic drink 'Hepalyse' gains loyal support through unique formulation amid many rivals
High-quality products in cosmetics via joint development with Shiseido
Ibube family as founding family maintains long-term stable corporate culture
Past new employee training issue prompted labor environment review and HR management strengthening
Multiple major banks listed as main shareholders, indicating strong financial trust
Leverages multiple overseas bases for localized compliance with local regulations
Active participation in industry groups like Health Future Creation Research Group contributing to new business development

Future Outlook

Growth Drivers

Increased demand for gastrointestinal treatments due to aging population
Expanded awareness and customer base for OTC drugs
Expansion of local manufacturing and sales networks overseas
Success in new treatment drug R&D
Rising health consciousness boosting functional food demand
Promotion of regulatory-compliant product development and approvals
Portfolio diversification via M&A
Productivity improvements through IT and digital technologies
Brand strengthening and expanded consumer touchpoints
Social trust via sustainability efforts
Expansion of new drugs and treatment indications
Organizational enhancement through talent development and training

Strategic Goals

Achieve over 40% overseas sales ratio
Expand new product sales by 30%
Achieve sustainability goals (CO2 reduction, etc.)
Develop and commercialize new prescription functional materials
30% business efficiency improvement via digitalization
Risk diversification through business diversification
Establish highest customer satisfaction in health-related businesses
Strengthen global collaboration in R&D and manufacturing
Advanced talent development programs and diversity promotion
Maintain leadership and trust in pharmaceutical industry

Business Segments

Prescription Pharmaceutical Manufacturing and Sales

Overview

Manufactures and sells prescription pharmaceuticals centered on gastrointestinal drugs to medical institutions, providing high-quality products.

Competitiveness

Development expertise in gastrointestinal prescription drugs and European market expansion

Customers

Medical institutions
Hospitals
Clinics
Pharmacies
Pharmaceutical wholesalers
Overseas sales agents
Medical research institutions
Specialist physicians
Pharmaceutical developers
Hospital groups

Products

Promac
Ashinon
Peon
Landel
Answer 20 Injection
Asacol
Acofide
Ulcerative Colitis Treatments
Gastrointestinal Therapeutics
Gastrointestinal Medicines
Liver Disease Treatments
Biologics
Immunomodulators
Prescription Injections
Prescription Skincare Products

Over-the-Counter Drug Sales Support

Overview

Provides sales support, marketing, and distribution management for pharmaceuticals and health foods targeted at general consumers.

Competitiveness

Industry-leading chondroitin brand power and diverse sales channels

Customers

Pharmacy chains
Drugstores
Retail stores
Pharmaceutical wholesale distributors
Mail-order companies
Online pharmacies
Health food stores
Convenience stores
Health-related stores

Products

Chondroitin Formulations
Toncs
Laxatives
Skincare Products
Eye Drops
Soft Drinks
Health Supplements
Cosmetics
Supplements
Moisturizing Lotions

Overseas Pharmaceutical Business

Overview

Advances pharmaceutical manufacturing, sales, and R&D in overseas markets, primarily in Europe and Asia.

Competitiveness

R&D capabilities compliant with European regulations and multinational network

Customers

European medical institutions
Asian sales agents
International pharmaceutical wholesalers
Overseas research institutions
Local pharmaceutical companies
Government health agencies
Overseas hospitals
International health organizations

Products

Tylotix Brand Pharmaceuticals
Ulcerative Colitis Treatments
Prescription Gastrointestinal Drugs
High-Function Pharmaceuticals
Europe-Market Products
International Supply Chain
Export OTC Drugs

R&D Outsourcing & Collaboration

Overview

Provides advanced technical support for pharmaceuticals and healthcare products through contract research and joint development.

Competitiveness

High-precision contract services leveraging long years of pharmaceutical development experience

Customers

Pharmaceutical companies
Biotech ventures
University research institutions
Medical device manufacturers
Investment funds
Government research institutions
Cosmetics companies
Health food manufacturers

Products

New Ingredient Screening
Clinical Trial Support
Research Reagents
Formulation Development
Safety Evaluation
Efficacy Evaluation
Contract Research
Technology Transfer

Logistics & Distribution Support

Overview

Provides logistics services including strict quality and temperature control for pharmaceuticals.

Competitiveness

Logistics optimization based on pharmaceutical-specific quality management expertise

Customers

Pharmaceutical manufacturers
Distributors
Retailers
Wholesalers
Medical institutions
Mail-order companies
Cold chain delivery companies

Products

Pharmaceutical Logistics Management
Warehouse Storage Services
Delivery Management
Temperature Control Systems
Inventory Management
Quality Assurance Management

Health Food OEM & Contract Manufacturing

Overview

Supports OEM and contract manufacturing for health foods utilizing proprietary technologies.

Competitiveness

Manufacturing technology pursuing both functionality and safety

Customers

Health food manufacturers
Mail-order businesses
Pharmacy chains
Cosmetics companies
Beverage manufacturers
Nutritional supplement companies

Products

Health Food Manufacturing
Supplement OEM
Functional Labeled Food Manufacturing
Soft Drink Manufacturing

Competitive Advantage

Strengths

Expertise in gastrointestinal treatments
Top chondroitin formulation brand
International expansion centered on Europe
Diverse product portfolio
Long years of R&D experience
Strong OTC sales network
Solid financial base
Synergy with subsidiaries and overseas bases
Combined prescription and OTC strategy
Continuous technological innovation
High-quality manufacturing management
Regionally specialized products
Trusted brand image
Regulatory compliance expertise
Strong commitment to safety and quality

Competitive Advantages

High market share in gastrointestinal pharmaceuticals domestically and internationally
Differentiation through proprietary technology and diverse chondroitin products
Superior position in Europe and Asia via local production and subsidiaries
Broad customer coverage combining prescription and OTC
Robust R&D for new and improved drugs
Investment capacity supported by stable capital base
International standards compliance in quality management
Optimized consumer touchpoints via multi-channel sales
Strong transaction network with prescription wholesalers and pharmacies
Brand strategy earning trust from healthcare professionals
Overseas R&D base via Swiss Tylotix acquisition
Focus on proprietary ingredients and expanded indications
Risk dispersion through broad product lineup
Portfolio expansion via active M&A
Flexible development for niche markets

Threats

Intense domestic and international pharmaceutical competition
Price pressure from generics
Stricter regulations and approval delays
Profit deterioration from exchange rate fluctuations
Intensified competition from new entrants
Decline in product competitiveness due to patent expirations
Risk of reputational damage (past scandals, etc.)
Market contraction from healthcare cost-cutting policies
Rising raw material prices
Political and economic uncertainty in overseas markets
Risk of quality issues in manufacturing
Increasing cyber security threats

Innovations

2024: Prevalin α Quick Launch Preparation

Overview: Developing a new antihistamine-enhanced ointment formulation scheduled for November 2024 launch.
Impact: Contributes to competitive advantage in skin condition treatment market

2023: Enhanced Research on Next-Generation Gastrointestinal Treatments

Overview: Developing new ulcerative colitis drug leveraging Swiss Tylotix technology.
Impact: Expected to expand share and achieve high profitability in European market

2022: Introduction of Digital Manufacturing Management System

Overview: Implemented latest IT for quality control and efficiency in manufacturing processes.
Impact: Achieved cost reduction and uniform product quality

2021: Relaunch of New Wiz One Laxative

Overview: Reduced additives and optimized ingredients to shorten dosage period.
Impact: Successfully improved user satisfaction and market competitiveness

2020: Acquisition of Subsidiary Nissui Seiyaku Pharmaceutical Sales Shares

Overview: Made sales subsidiary a wholly-owned subsidiary to strengthen sales capabilities.
Impact: Achieved sales efficiency through integrated sales structure

Sustainability

Energy-saving in manufacturing processes and reduction of greenhouse gas emissions
Acquisition and maintenance of international standards for pharmaceutical quality management
Active promotion of health awareness activities in local communities
Ongoing waste reduction and improved recycling rates
Enhanced safety and health management and workplace environment improvements